A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Nature Chemical Biology

Volumn 11, Issue 6, 2015, Pages 432-437

  Chan Penebre, Elayne ^a   Kuplast, Kristy G ^a   Majer, Christina R ^b   Boriack Sjodin, P Ann ^a   Wigle, Tim J ^b   Johnston, L Danielle ^a   Rioux, Nathalie ^a   Munchhof, Michael J ^a   Jin, Lei ^c   Jacques, Suzanne L ^a   West, Kip A ^a   Lingaraj, Trupti ^a   Stickland, Kimberly ^a   Ribich, Scott A ^a   Raimondi, Alejandra ^a   Scott, Margaret Porter ^d   Waters, Nigel J ^a   Pollock, Roy M ^b   Smith, Jesse J ^a   Barbash, Olena ^e   Pappalardi, Melissa ^e   Ho, Thau F ^e   Nurse, Kelvin ^e   Oza, Khyati P ^e   Gallagher, Kathleen T ^e   Kruger, Ryan ^e   Moyer, Mikel P ^f   Copeland, Robert A ^a   Chesworth, Richard ^a   Duncan, Kenneth W ^a   more..

^a EPIZYME INC   (United States)

^b Warp Drive Bio ^*  (United States)

^c Agile Biostructure Solutions   (United States)

^d GENENTECH INC   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Raze Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GSK3235025; ISOQUINOLINE DERIVATIVE; PRMT5 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN BINDING; PYRIMIDINE DERIVATIVE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SNRPD3 PROTEIN, HUMAN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HUMAN; IC50; INBRED MOUSE STRAIN; LYMPHOMA, MANTLE-CELL; MALE; METABOLISM; METHYLATION; PATHOLOGY; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; LYMPHOMA, MANTLE-CELL; MALE; METHYLATION; MICE, INBRED STRAINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN-ARGININE N-METHYLTRANSFERASES; PYRIMIDINES; SNRNP CORE PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937397052     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1810     Document Type: Article

References (51)

1. Chung, J. et al. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. J. Biol. Chem. 288, 35534-35547 (2013).
2. Wang, L., Pal, S. & Sif, S. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol. Cell. Biol. 28, 6262-6277 (2008).
3. Pal, S. et al. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 26, 3558-3569 (2007).
4. Wei, T.-Y.W. et al. Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci. 103, 1640-1650 (2012).
5. Powers, M.A., Fay, M.M., Factor, R.E., Welm, A.L. & Ullman, K.S. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 71, 5579-5587 (2011).
6. Cho, E.C. et al. Arginine methylation controls growth regulation by E2F1. EMBO J. 31, 1785-1797 (2012).
7. Pal, S., Vishwanath, S.N., Erdjument-Bromage, H., Tempst, P. & Sif, S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 24, 9630-9645 (2004).
8. Karkhanis, V., Hu, Y.-J., Baiocchi, R.A., Imbalzano, A.N. & Sif, S. Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem. Sci. 36, 633-641 (2011).
9. Pollack, B.P. et al. The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J. Biol. Chem. 274, 31531-31542 (1999).
10. Wolf, S.S. The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans. Cell. Mol. Life Sci. 66, 2109-2121 (2009).
11. Yang, Y. et al. PRMT9 is a Type II methyltransferase that methylates the splicing factor SAP145. Nat. Commun. doi:10.1038/ncomms7428 (2015).
12. Boisvert, F.-M., Côté, J., Boulanger, M.-C. & Richard, S. A proteomic analysis of arginine-methylated protein complexes. Mol. Cell. Proteomics 2, 1319-1330 (2003).
13. Dhar, S. et al. Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. Sci. Rep. 3, 1311 (2013).
14. Gonsalvez, G.B. et al. Two distinct arginine methyltransferases are required for biogenesis of Sm-class ribonucleoproteins. J. Cell Biol. 178, 733-740 (2007).
15. Friesen, W.J. et al. The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Mol. Cell. Biol. 21, 8289-8300 (2001).
16. Meister, G. et al. Methylation of Sm proteins by a complex containing PRMT5 and the putative U snRNP assembly factor pICln. Curr. Biol. 11, 1990-1994 (2001).
17. Cheng, D. et al. Novel 3,5-Bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity. J. Med. Chem. 54, 4928-4932 (2011).
18. Cheng, D. et al. Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem. 279, 23892-23899 (2004).
19. Dowden, J. et al. Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1. Org. Biomol. Chem. 9, 7814-7821 (2011).
20. Huynh, T. et al. Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett. 19, 2924-2927 (2009).
21. Purandare, A.V. et al. Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett. 18, 4438-4441 (2008).
22. Therrien, E. et al. 1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett. 19, 6725-6732 (2009).
23. Wan, H. et al. Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)-Hit to Lead studies. Bioorg. Med. Chem. Lett. 19, 5063-5066 (2009).
24. Liu, F. et al. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J. Med. Chem. 56, 2110-2124 (2013).
25. Obianyo, O. et al. A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. ChemBioChem 11, 1219-1223 (2010).
26. Smil, D. et al. Discovery of a dual PRMT5-PRMT7 inhibitor. ACS Med. Chem. Lett. doi:10.1021/ml500467h (2015).
27. Alinari, L. et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood doi:10.1182/blood-2014-12-619783 (2015).
28. Kaniskan, H.Ü. et al. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew. Chem. Int. Ed. Engl. doi:10.1002/anie.201412154 (2015).
29. Copeland, R.A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists 2nd edn. (John Wiley & Sons, 2013).
30. Baell, J.B. & Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010).
31. Sneeringer, C.J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 107, 20980-20985 (2010).
32. Lor, L.A. et al. A simple assay for detection of small-molecule redox activity. J. Biomol. Screen. 12, 881-890 (2007).
33. Wang, M., Xu, R.-M. & Thompson, P.R. Substrate specificity, processivity, and kinetic mechanism of protein arginine methyltransferase 5. Biochemistry 52, 5430-5440 (2013).
34. Antonysamy, S. et al. Crystal structure of the human PRMT5:MEP50 complex. Proc. Natl. Acad. Sci. USA 109, 17960-17965 (2012).
35. Sun, L. et al. Structural insights into protein arginine symmetric dimethylation by PRMT5. Proc. Natl. Acad. Sci. USA 108, 20538-20543 (2011).
36. Dougherty, D.A. The cation-p interaction. Acc. Chem. Res. 46, 885-893 (2013).
37. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
38. Daigle, S.R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
39. Knutson, S.K. et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13, 842-854 (2014).
40. Knutson, S.K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
41. Aggarwal, P. et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 18, 329-340 (2010).
42. McCurdy, A., Jimenez, L., Stauffer, D.A. & Dougherty, D.A. Biomimetic catalysis of SN2 reactions through cation-.pi. interactions. The role of polarizability in catalysis. J. Am. Chem. Soc. 114, 10314-10321 (1992).
43. Wasilko, D. Titerless infected-cells preservation and scale-up. BioProcessing Journal 5, 29-32 (2006).
44. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
45. Evans, P.R. & Murshudov, G.N. How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
46. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology: Macromolecular Crystallography, Part A, Vol. 276 (eds Carter, C.W. Jr. & Sweet, R.) Ch. 19 (Academic Press, 1997).
47. Schüttelkopf, A.W. & van Aalten, D.M.F. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).
48. Winn, M.D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
49. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
50. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
51. Karlsson, R., Katsamba, P.S., Nordin, H., Pol, E. & Myszka, D.G. Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem. 349, 136-147 (2006).